 WESTMER, Colo., May 11, 2021 GLOBE NEWSWIRE -- ARCA biopharma, Inc. Nasdaq: ABIO, a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2021 financial results and provided a corporate update. 